Biocortech tests encompass clinical diagnostic and drug screening assays
Diagnostic and/or predictive biological test of depression and/or of depression severity (i.e., risk of suicidal behavior)
First clinical trial started early 2009. This pilot trial aims at achieving a proof of concept of the test among a sub-population of patients
Drug screening assay of predictive neuropsychiatric toxicology of new chemical entities
EDITOX® is a proprietary assay able to characterize CNS side effects of drugs (anti-depressant, anti-obesity…) in their preclinical phase. Biocortech is now launching this offer on a fee for service basis.